SEP 20, 2020 8:30 AM PDT

New Drug Combo Prolongs Survival with Advanced Kidney Cancer

WRITTEN BY: Annie Lennon

Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those with advanced kidney cancer. 

During trials, immunotherapy drug Opdivo and kinase inhibitor Cabometyx were shown to reduce the risk of death by kidney cancer by 40% when compared to Sutent, also a kinase inhibitor, and the former standard of care by Pfizer. Patients on the combination lived twice as long without their cancer progressing- an average of 16.6 months as opposed to 8.3 months for those on Sutent. 

More than this, twice as many patients on Opdivo-Cabometyx responded to the treatment and saw long-lasting effects. While 27% of trial patients responded to Sutent, 56% benefited from the new drug combination. All in all, those on the combo responded for a median of 20.2 months, whereas those on Sutent responded for a median of 11.5 months. 

As such, Bristol Myers is currently in the process of gaining the treatment FDA approval for the treatment and is advocating its use among those with advanced kidney cancer.  

Although promising, the new drug combination seems to have similar efficacy to Merck’s own drug combination- Keytruda, an immunotherapy drug, and Inlya, a kinase inhibitor by Pfizer. Together, these drugs were able to cut the risk of death by between 41% and 46% among patients with the condition. 

“The various combination treatments will unlikely be compared head-to-head,” says Toni Choueiri, MD of Dana-Farbar Cancer Institute and author of the Opdivo-Cabometyx trial. “But I think the quality of life could differentiate this new therapy, as there was a statistical significance favoring the combination arm with both questionnaires we used.”

Despite the optimism, many in the medical community are still uncertain as to whether treating cancer with two immunotherapies or immunotherapy alongside a kinase-inhibiting drug is better. However, as both seem to have similar effectiveness, some say that both should nevertheless be seen as a standard of care for first-line patients. 

 

Sources: Fierce PharmaSTAT

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 09, 2020
Microbiology
Fighting COVID-19 with Help From Llamas
NOV 09, 2020
Fighting COVID-19 with Help From Llamas
Camelids, which include llamas, alpacas and camels have immune systems that generate two kinds of antibodies when confro ...
DEC 27, 2020
Genetics & Genomics
Delivering DNA- & RNA-Based Therapies in a New Way
DEC 27, 2020
Delivering DNA- & RNA-Based Therapies in a New Way
Gene therapy holds tremendous promise for its potential to cure genetic diseases. We've also recently seen how critical ...
DEC 28, 2020
Cell & Molecular Biology
How an Herbal Compound May Fight Pancreatic Cancer
DEC 28, 2020
How an Herbal Compound May Fight Pancreatic Cancer
For centuries, Chinese practitioners have used herbs to treat all kinds of ailments. New research has shown that one of ...
DEC 28, 2020
Immunology
Inhaling a Puff of Llama Antibodies to Relieve COVID
DEC 28, 2020
Inhaling a Puff of Llama Antibodies to Relieve COVID
Scientists at the National Institutes of Health have identified new antibody-based weapons in the fight against COVID-19 ...
JAN 20, 2021
Drug Discovery & Development
Designer Cytokine: Potential Therapeutic Approach for Paralysis
JAN 20, 2021
Designer Cytokine: Potential Therapeutic Approach for Paralysis
Paralysis due to spinal cord damage remains an irreparable condition. However, a new therapeutic approach may bring rene ...
JAN 22, 2021
Drug Discovery & Development
Treating NF1: Investigational Drug Shows Positive Results
JAN 22, 2021
Treating NF1: Investigational Drug Shows Positive Results
From preclinical studies, researchers have found that an investigational drug called ‘cabozantinib’ can trea ...
Loading Comments...